Search   |  Advanced

Research Summary

Home- versus Office-based Buprenorphine Induction: Impact on Opioid and Other Drug Use

Home-based buprenorphine induction is gaining increasing attention, yet adequate description and evaluation of this novel strategy is lacking. Prior analysis showed that 30-day treatment retention was similar among patients choosing home-based versus office-based induction. In this subgroup analysis of the same observational cohort, 79 patients who chose either home-based or office-based induction were assessed to determine the association between induction strategy and drug-use outcomes over 6 months. Data analysis included mixed nonlinear models.

  • Compared with office-based induction, participants choosing home-based induction:
    • had no significant differences in self-reported opioid use.
    • had a greater reduction in self-reported use of other drugs (adjusted odds ratio, 0.05).


Although limited by small sample size, lack of randomization, and self-reported drug use rather than urine toxicology testing, these results suggest that location of induction may have no effect on drug use outcomes. Larger experiments with assessment of safety and patient satisfaction are needed. Jeanette M. Tetrault, MD


Cunningham CO, Giovanniello A, Li X, et al. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. J Subst Abuse Treat. 2011;40(4):349–356.